{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:40:08Z","timestamp":1758937208735,"version":"3.44.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.leukres.2022.106923","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T12:47:06Z","timestamp":1659617226000},"page":"106923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tyrosine kinase inhibitor dose reduction during the management of accelerated phase chronic myeloid leukemia"],"prefix":"10.1016","volume":"121","author":[{"given":"Guillermo","family":"Ort\u00ed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valent\u00edn","family":"Garc\u00eda-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiomar","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"Ferrer-Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolando","family":"Vallansot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Xicoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c0ngela","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Triguero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Felipe","family":"Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.leukres.2022.106923_bib1","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.leukres.2022.106923_bib2","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2022.106923_bib3","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/leu.2012.92","article-title":"First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia","volume":"26","author":"Rea","year":"2012","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2022.106923_bib4","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/leu.2011.323","article-title":"Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results","volume":"26","author":"le Coutre","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.leukres.2022.106923_bib5","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2010.110","article-title":"Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy","volume":"24","author":"Giles","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2022.106923_bib6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clml.2013.08.008","article-title":"Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase","volume":"14","author":"Ohanian","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"9","key":"10.1016\/j.leukres.2022.106923_bib7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ajh.24034","article-title":"Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance\/intolerance to imatinib and other tyrosine kinase inhibitors","volume":"90","author":"Gambacorti-Passerini","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"19","key":"10.1016\/j.leukres.2022.106923_bib8","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.leukres.2022.106923_bib9","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2022.106923_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-016-2839-z","article-title":"Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response","volume":"96","author":"Cervantes","year":"2017","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2022.106923_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cncr.32504","article-title":"Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2022.106923_bib12","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","author":"Cortes","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2022.106923_bib13","doi-asserted-by":"crossref","first-page":"e902","DOI":"10.1016\/S2352-3026(21)00333-1","article-title":"Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial","volume":"8","author":"Murai","year":"2021","journal-title":"Lancet Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2022.106923_bib14","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2022.106923_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25907","article-title":"The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia","author":"Ohanian","year":"2020","journal-title":"Am. J. Hematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:02:31Z","timestamp":1758934951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622001497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":15,"alternative-id":["S0145212622001497"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106923","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tyrosine kinase inhibitor dose reduction during the management of accelerated phase chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106923","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106923"}}